Drug and diagnostic company Agenix Limited (AGX) announced that Japan’s Patent Office had granted a key patent covering the manufacturing process of its ThromboView® imaging agent for the detection of blood clots in humans. It covers humanized antibodies derived from DD-3B6/22 specific for the D-dimer fragment of fibrin provides long-term protection for the company’s technology through broad claims over methods of manufacture and use. It is a major asset in the commercialisation of ThromboView and establishing strategic business partnerships with global pharmaceutical and medical diagnostic companies. ThromboView is now protected by multiple patents in the Japan, the United States, Europe, Singapore, Australia and New Zealand, with the granting of patents for China and Canada pending. The patents provide protection for ThromboView out to 2022 with possible Hatch- Waxman term extension out to 2027.
Agenix Chairman and Chief Executive Officer, Nicholas Weston said, “The granting of patent protection in Japan confers further certainty and significantly increases the commercial value of the ThromboView diagnostic technology globally. In conjunction with the other patents covering the use and production of ThromboView, this new patent delivers a major commercial advantage to Agenix in one of the world’s leading markets for diagnostic imaging and manufacturing.”
ThromboView is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited. Agenix is a public, clinical-stage company focused on the discovery and development of innovative monoclonal antibody blood clot diagnostics, and small molecule drugs for the treatment of hepatitis B and other serious diseases. Agenix is a leading Australian biotechnology company and was developer of the widely used in vitro D-dimer diagnostic blood test. Agenix Limited is committed to generating next generation drugs and diagnostics.